SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (251)11/8/2001 2:23:46 PM
From: Gary Mohilner  Read Replies (1) | Respond to of 1022
 
Richard,

You have to look at what the new toxin's are doing. Ricin was large celled which evoked an immune response. Toxin's like DM1, which IMGN has in clinical trials, are far more powerful small molecules that have proven safe thus far in clinical trials. As successful as Herceptin's been, look at the preclinical results DNA's getting with Herceptin-DM1 in the reports they recently issued at AACR.

MAB's by themselves generally have needed to work in conjunction with other forms of chemo. TAP drugs carry the toxin to the cancerous cell, but that doesn't mean they won't work with other forms of chemo, especially if the other form of chemo attacks the cancerous cells not identified by the MAB that's part to the TAP.

In IMGN's preclinical trials of N901-DM1 they achieved essentially the same results in mice with 10% of the MTD of N901-DM1 when combined with Taxol. In both cases they were curing small cell lung cancer in mice essentially 100% of the time. The drug is just months into a Phase I Trial, about all that's know is it's being well tolerated and doses continue to escalate. More should be known by ASCO.

Don't get me wrong, naked MAB's may have there place in medicine, but I believe TAP drugs will prove to be curative themselves in some cases, whereas naked MAB's will rely on other forms of chemo to work, perhaps including some TAP drugs.

Gary